11-73975136-T-A
Variant names:
Variant summary
Our verdict is Benign. The variant received -10 ACMG points: 0P and 10B. BP4_StrongBP6_ModerateBS2
The NM_003355.3(UCP2):c.816-15A>T variant causes a intron change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.000299 in 1,601,194 control chromosomes in the GnomAD database, including 2 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Benign (★).
Frequency
Genomes: 𝑓 0.00077 ( 0 hom., cov: 32)
Exomes 𝑓: 0.00025 ( 2 hom. )
Consequence
UCP2
NM_003355.3 intron
NM_003355.3 intron
Scores
2
Clinical Significance
Conservation
PhyloP100: 0.527
Publications
0 publications found
Genes affected
UCP2 (HGNC:12518): (uncoupling protein 2) Mitochondrial uncoupling proteins (UCP) are members of the larger family of mitochondrial anion carrier proteins (MACP). UCPs separate oxidative phosphorylation from ATP synthesis with energy dissipated as heat, also referred to as the mitochondrial proton leak. UCPs facilitate the transfer of anions from the inner to the outer mitochondrial membrane and the return transfer of protons from the outer to the inner mitochondrial membrane. They also reduce the mitochondrial membrane potential in mammalian cells. Tissue specificity occurs for the different UCPs and the exact methods of how UCPs transfer H+/OH- are not known. UCPs contain the three homologous protein domains of MACPs. This gene is expressed in many tissues, with the greatest expression in skeletal muscle. It is thought to play a role in nonshivering thermogenesis, obesity and diabetes. Chromosomal order is 5'-UCP3-UCP2-3'. [provided by RefSeq, Jul 2008]
UCP2 Gene-Disease associations (from GenCC):
- hyperinsulinism due to UCP2 deficiencyInheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet
Genome browser will be placed here
ACMG classification
Classification was made for transcript
Our verdict: Benign. The variant received -10 ACMG points.
BP4
Computational evidence support a benign effect (BayesDel_noAF=-0.71).
BP6
Variant 11-73975136-T-A is Benign according to our data. Variant chr11-73975136-T-A is described in ClinVar as [Benign]. Clinvar id is 1990457.Status of the report is criteria_provided_single_submitter, 1 stars.
BS2
High AC in GnomAd4 at 117 AD gene.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
UCP2 | NM_003355.3 | c.816-15A>T | intron_variant | Intron 7 of 7 | ENST00000663595.2 | NP_003346.2 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
UCP2 | ENST00000663595.2 | c.816-15A>T | intron_variant | Intron 7 of 7 | NM_003355.3 | ENSP00000499695.1 | ||||
UCP2 | ENST00000310473.10 | c.816-15A>T | intron_variant | Intron 8 of 8 | 1 | ENSP00000312029.3 | ||||
UCP2 | ENST00000536983.5 | c.635-15A>T | intron_variant | Intron 6 of 6 | 5 | ENSP00000441147.1 | ||||
UCP2 | ENST00000544615.5 | n.735-15A>T | intron_variant | Intron 4 of 4 | 2 |
Frequencies
GnomAD3 genomes AF: 0.000778 AC: 118AN: 151632Hom.: 0 Cov.: 32 show subpopulations
GnomAD3 genomes
AF:
AC:
118
AN:
151632
Hom.:
Cov.:
32
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD2 exomes AF: 0.000317 AC: 73AN: 230594 AF XY: 0.000273 show subpopulations
GnomAD2 exomes
AF:
AC:
73
AN:
230594
AF XY:
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.000249 AC: 361AN: 1449444Hom.: 2 Cov.: 30 AF XY: 0.000253 AC XY: 182AN XY: 720454 show subpopulations
GnomAD4 exome
AF:
AC:
361
AN:
1449444
Hom.:
Cov.:
30
AF XY:
AC XY:
182
AN XY:
720454
show subpopulations
African (AFR)
AF:
AC:
103
AN:
33022
American (AMR)
AF:
AC:
17
AN:
43046
Ashkenazi Jewish (ASJ)
AF:
AC:
0
AN:
25962
East Asian (EAS)
AF:
AC:
0
AN:
38966
South Asian (SAS)
AF:
AC:
0
AN:
84692
European-Finnish (FIN)
AF:
AC:
0
AN:
52814
Middle Eastern (MID)
AF:
AC:
7
AN:
5758
European-Non Finnish (NFE)
AF:
AC:
195
AN:
1105238
Other (OTH)
AF:
AC:
39
AN:
59946
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.498
Heterozygous variant carriers
0
19
39
58
78
97
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance
GnomAD4 genome AF: 0.000771 AC: 117AN: 151750Hom.: 0 Cov.: 32 AF XY: 0.000822 AC XY: 61AN XY: 74190 show subpopulations
GnomAD4 genome
AF:
AC:
117
AN:
151750
Hom.:
Cov.:
32
AF XY:
AC XY:
61
AN XY:
74190
show subpopulations
African (AFR)
AF:
AC:
98
AN:
41316
American (AMR)
AF:
AC:
3
AN:
15248
Ashkenazi Jewish (ASJ)
AF:
AC:
0
AN:
3470
East Asian (EAS)
AF:
AC:
0
AN:
5150
South Asian (SAS)
AF:
AC:
0
AN:
4806
European-Finnish (FIN)
AF:
AC:
0
AN:
10530
Middle Eastern (MID)
AF:
AC:
0
AN:
294
European-Non Finnish (NFE)
AF:
AC:
15
AN:
67922
Other (OTH)
AF:
AC:
1
AN:
2104
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.510
Heterozygous variant carriers
0
6
12
17
23
29
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance
Alfa
AF:
Hom.:
Bravo
AF:
Asia WGS
AF:
AC:
1
AN:
3478
ClinVar
Significance: Benign
Submissions summary: Benign:1
Revision: criteria provided, single submitter
LINK: link
Submissions by phenotype
not provided Benign:1
Oct 04, 2022
Labcorp Genetics (formerly Invitae), Labcorp
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing
- -
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
DANN
Benign
PhyloP100
RBP_binding_hub_radar
RBP_regulation_power_radar
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at
Publications
You must be logged in to view publications. This limit was set because tens of millions (!) of queries from AI bots are generated daily.